http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100920125-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 |
| filingDate | 2008-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100920125-B1 |
| titleOfInvention | Combination of pyrazolopyrimidinone compound and αadrenergic receptor antagonist for the treatment of benign prostatic hyperplasia |
| abstract | The present invention is a combination for the prophylaxis and treatment of benign prostatic hyperplasia and associated lower urinary tract symptoms, the prostatic hyperplasia and associated with it by administering a pyrazolopyrimidinone compound of formula (1) and alpha adrenergic receptor antagonist together A composition for simultaneous administration for treatment of lower urinary tract disorders.n n n The present invention not only shows side effects due to drug interaction by administering a compound of Formula 1, which is a kind of pyrazolopyrimidinone compound, and an alpha adrenergic receptor antagonist, but also exhibits a synergistic effect on prostate and bladder smooth muscle relaxation. When the drugs are used alone can be effectively used for the prevention and treatment of enlarged prostate and associated lower urinary tract symptoms. |
| priorityDate | 2007-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.